Recruitment:

​

 

 

​

​

​

​

​

Check out Mount Sinai's article on the ICARUS-IBD study: 

https://reports.mountsinai.org/article/gi2021-02-icarus

​

 

Our Publications:

​

1. McGregor CG, Adams A, Sadler R, Arancibia-Cárcamo CV, Palmer R, Ambrose T, Brain O, Walsh A, Klenerman P, Travis SP, Croft NM, Lindsay JO, Satsangi J. Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic. Gut. 2021 Dec;70(12):2398-2400. doi:  10.1136/gutjnl-2021-324116. Epub 2021 Feb 12. PMID: 33579788.

​

2. Wong SY, Gold S, Accorsi EK, Cowger TL, Wiseman D, Navalurkar R, Dixon R, Helmus DS, CiTIStudy Group, Firpo-Betancourt A, Mendu DR, Zolla-Pazner S, Cadwell K, Colombel JF. Safety of administering biologics to IBD patients at an outpatient infusion centre In New York City during the COVID-19 pandemic: Sars-CoV-2 seroprevalence and clinical and social characteristics. medRxiv 2021.03.15.21253615; doi: https://doi.org/10.1101/2021.03.15.21253615. 

 

3. Wellens J, Colombel JF, Satsangi JJ, Wong SY. SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges. J Crohn’s Colitis. 2021 Aug 2;15(8):1376-1386. doi: 10.1093/ecco-jcc/jjab046. PMID: 33721882; PMCID: PMC7989537.

 

4. Wong SY, Dixon R, Martinez Pazos V, Gnjatic S, Colombel JF, Cadwell K; ICARUS-IBD Working Group. Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. Gastroenterology. 2021 Aug;161(2):715-718.e4. doi: 10.1053/j.gastro.2021.04.025. Epub 2021 Apr 20. PMID: 33887219; PMCID: PMC8055494.

 

5. McNaughton AL, Paton RS, Edmans M, Youngs J, Wellens J, …, Klnerman P, Gupta S, Thompson CP. Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. medRxiv 2021.05.04.21256571; doi: https://doi.org/10.1101/2021.05.04.21256571

 

6. Selim R, Wellens J, Marlow L, Satsangi J. SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy. Lancet Gastroenterol. Hepatol. October 2021. doi: https://doi.org/10.1016/S2468-1253(21)00347-2.

 

7. Wellens J, Brann S, Adams A, Marlow L, Lindsay J, Satsangi J, Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease. Lancet Gastroenterol. Hepatol. April 2022; doi: https://doi.org/10.1016/S2468-1253(22)00120-0.

 

8. McNaughton A, ….., Thompson C. Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. JCI Insight. May 2022. doi: https://doi.org/10.1172/jci.insight.156372

​

9. Selim R, Wellens J, Brann S, Marlow L, Adams A, Satsangi J. Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy. Lancet Gastroenterol. Hepatol. September 2022. doi: https://doi.org/10.1016/S2468-1253(22)00302-8